Monitor for any shareholder dissent on the authorized share increase or compensation votes. The increase in authorized shares could be used for future financing or acquisitions, but no immediate plans disclosed. Trading volume and price action around the June 10 meeting may reflect sentiment on the proposals.
IOVA drugs
IOVA drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 29 $3.31entry
- T+1 · 7mo ago +1.51%α +0.49% · $3.36
- T+5 · 7mo ago +23.57%α +20.45% · $4.09
- T+20 · 6mo ago +29.91%α +23.86% · $4.30
- T+60 · 4mo ago +50.76%α +46.64% · $4.99
Price Chart
How similar events traded
Executive Summary
Iovance Biotherapeutics filed additional definitive proxy materials for its 2026 Annual Meeting, with proposals including director elections, say-on-pay, auditor ratification, an ESPP share increase, and a 30% increase in authorized common stock from 500M to 650M shares. The board recommends 'For' on all items. The filing is routine with no activist or dissident involvement.
Key Financial Metrics
Key Facts
- Annual Meeting scheduled for June 10, 2026, voting deadline June 9, 2026
- Proposal 1: Election of six directors (Iain Dukes, Athena Countouriotis, Ryan Maynard, Wayne P. Rothbaum, Frederick G. Vogt, Michael Weiser)
- Proposal 5: Increase ESPP shares by 1,000,000
- Proposal 6: Increase authorized common stock from 500M to 650M shares (30% increase)
- Board recommends 'For' on all proposals
- No activist or dissident solicitation; management filed the proxy
Financial Impact
Authorized share increase of 150M shares, potential for future dilution; ESPP increase of 1M shares is minor
Risk Factors
- Potential dilution from authorized share increase if fully issued
- Possible negative vote on say-on-pay or director elections could signal governance concerns
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001104659-26-050467 |
| Document: 0001104659-26-050467-index-headers.html | 0001104659-26-050467 |
| Document: 0001104659-26-050467-index.html | 0001104659-26-050467 |
| Document: 0001104659-26-050467.txt | 0001104659-26-050467 |
Track record
21 reports on IOVA
3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +121.97% at T+60 after the Jun 10, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $8.08 Now $7.55 −6.56% settles Dec 9
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $8.04 Now $7.55 −6.09% settles Dec 7
- Nov 5, 202611d ago 8-K Bullish 6/10 Entry $7.74 Now $7.55 −2.45% settles Dec 4
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $8.70 Now $7.55 −13.22% settles Dec 3
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $8.48 Now $7.55 −10.97% settles Nov 30
- Oct 28, 202619d ago Press Release Bullish 7/10 Entry $9.56 Now $7.55 −21.03% settles Nov 27
- Oct 5, 20266w ago 8-K Neutral 4/10 Entry $12.96 to $8.65 Now $7.55 −41.74% ▼ −33.25% −30.34% vs SPY
- Oct 2, 20266w ago 3 Neutral 2/10 Entry $14.15 to $7.93 Now $7.55 −46.64% ▼ −43.99% −41.42% vs SPY
- Sep 29, 20266w ago 8-K Bullish 6/10 Entry $14.45 to $14.58 Now $7.55 −47.75% ▲ +0.90% +0.19% vs SPY
- Aug 21, 202612w ago Press Release Neutral 2/10 Entry $8.06 to $10.64 Now $7.55 −6.33% ▲ +32.01% +30.70% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers